or Try an Advanced Search...

    Stage Biopharmaceutical Stocks List

    Symbol Grade Name % Change
    KURA C Kura Oncology, Inc. -3.52
    OCGN C Ocugen, Inc. -3.54
    CRBP C Corbus Pharmaceuticals Holdings, Inc. -2.00
    CADL C Candel Therapeutics, Inc. -9.45
    AXSM C Axsome Therapeutics, Inc. -1.05
    CRVS C Corvus Pharmaceuticals, Inc. 4.57
    CTNM C Contineum Therapeutics, Inc. 3.61
    RZLT C Rezolute, Inc. 3.13
    IMTX D Immatics N.V. 1.39
    PLRX D Pliant Therapeutics, Inc. -2.18
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - General
    Related Stock Lists: Medicine Clinical Medicine Cancer Chemotherapy Depression Disease Hypertension Organ Systems Pancreatic Cancer Pulmonary Arterial Hypertension Radiation Advanced Solid Tumors Ajulemic Acid Alcohol Alzheimer's Disease Antibiotics Antidepressants Antineoplastic Drugs Antiviral Therapies Attention Deficit Hyperactivity Disorder

    Related ETFs - A few ETFs which own one or more of the above listed Stage Biopharmaceutical stocks.

    Symbol Grade Name Weight
    XPH D SPDR S&P Pharmaceuticals ETF 5.5
    PILL F Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF 4.41
    SBIO C ALPS Medical Breakthroughs ETF 3.77
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 2.88
    CNCR D Loncar Cancer Immunotherapy ETF 2.4
    View all Stage Biopharmaceutical ETFs...
    Compare ETFs
    Compare SBIO to CNCR Compare XPH to BBC Compare XPH to CNCR

        Stage Biopharmaceutical Stocks Recent News

        Date Stock Title
        May 17 OCGN DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session
        May 16 RZLT Rezolute reports Q3 results
        May 16 OCGN Nayax Posts Weak Q1 Results, Joins GameStop, Iris Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
        May 15 RZLT Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
        May 15 OCGN Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
        May 15 OCGN Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...
        May 15 OCGN Q1 2024 Ocugen Inc Earnings Call
        May 14 CADL Candel Therapeutics GAAP EPS of -$0.28
        May 14 OCGN Ocugen, Inc. (OCGN) Q1 2024 Earnings Call Transcript
        May 14 PLRX Pliant reports phase 2 data on idiopathic pulmonary fibrosis asset bexotegrast
        May 14 OCGN Ocugen GAAP EPS of -$0.05 beats by $0.01, revenue of $1.01M
        May 14 CADL Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
        May 14 OCGN Ocugen Provides Business Update with First Quarter 2024 Financial Results
        May 14 KURA Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
        May 14 PLRX Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
        May 14 IMTX Immatics reports Q1 results
        May 14 IMTX Immatics Announces First Quarter 2024 Financial Results and Business Update
        May 13 AXSM 15 Most Depressed States in the US
        May 13 CRBP Corbus Pharmaceuticals a new outperform at RBC on cancer, obesity assets
        May 13 OCGN Ocugen Q1 2024 Earnings Preview
        Related Industries: Biotechnology Drug Manufacturers - General
        Related Stock Lists: Medicine Clinical Medicine Cancer Chemotherapy Depression Disease Hypertension Organ Systems Pancreatic Cancer Pulmonary Arterial Hypertension Radiation Advanced Solid Tumors Ajulemic Acid Alcohol Alzheimer's Disease Antibiotics Antidepressants Antineoplastic Drugs Antiviral Therapies Attention Deficit Hyperactivity Disorder
        Stage Biopharmaceutical

        Browse All Tags